Overview

Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma

Status:
Unknown status

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

Clinical and pharmacokinetic data suggest that the effect of rituximab could be improved by prolonged exposure to the drug. To test for this hypothesis we performed a prospective randomized trial of rituximab maintenance therapy versus observation in patients (pts) with aggressive CD20+ B-cell lymphoma and mantle cell lymphoma.

Phase:

Phase 3

Details

Lead Sponsor:

University Hospital Heidelberg

Treatments:

Rituximab